对于古塞尔库马布来说,抑制IL-23的双重机制是否有助于性结肠炎?
1School of Pharmacy and Medical Sciences, Gold Coast Campus, Griffith University, Gold Coast, Queensland, Australia.
Expert opinion on biological therapy
|May 21, 2025
概括
一种IL-23抑制剂Guselkumab在性结肠炎 (UC) 患者中改善了临床缓解,而这些患者对其他疗法反应不足. QUASAR试验没有显示过多的不良事件,这表明这种UC治疗的安全性概况有利.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 性结肠炎 (UC) 涉及免疫调节失调,目前的免疫抑制剂和生物制剂等疗法往往不足或耐受不佳.
- 现有的UC治疗方法可能无法提供足够的缓解或导致某些患者的不耐受性.
研究的目的:
- 评估双机制IL-23抑制剂guselkumab在患有中度至重度UC的患者中的疗效和安全性.
- 评估古塞尔库马布在诱导和维持UC患者临床缓解的性能,这些患者对现有治疗没有充分反应或不能容忍现有治疗.
主要方法:
- QUASAR试验是一项3期研究,评估了古塞尔库马布在中度至重度UC的患者身上.
- 参与者对皮质类固醇,免疫抑制剂,生物药物或氏激酶 (JAK) 抑制剂有不充分的反应或不耐受.
- 该研究包括诱导和维持阶段,以评估随时间推移的治疗有效性.
主要成果:
- 在诱导和维持阶段,古塞尔库马布治疗使UC患者的临床缓解率提高.
- 在维持部分后临床缓解的好处为24个百分点 (45%对21%).
- 与安慰剂相比,与guselkumab没有观察到过多的不良事件,这表明安全性很好.
结论:
- 古塞尔库马布是中度至重度UC的有效治疗选择,特别是在对其他疗法反应不足或不耐受的患者中.
- 与其他IL-23抑制剂相比,Guselkumab显示出潜在的优越疗效,可能是由于其双重机制,包括CD64受体阻断.
- 需要进一步进行直接比较试验,以确认古塞尔库马布与其他IL-23抗剂的比较疗效.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
130
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
130
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Inflammatory Bowel Disease IV: Pharmacological Management
122
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
122
T Cell Types and Functions
963
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
963


